Pluripotent stem cell (PSC) differentiation into cardiomyocytes 

Directed cardiomyocyte differentiation of human induced pluripotent stem cells (hPSCs) is a major tool for development of disease models, drug screening platforms, and cellular therapies. Our workflow offers consistent, timesaving, and reliable hPSC differentiation solutions resulting in cardiomyocytes ready for any downstream application.

With a focus on maintaining consistency, viability and reliability of cells, our workflow is inclusive of solutions for cell differentiation, culture, isolation and characterization and thus enables the differentiation of cells for further applications.

PSC differentiation into cardiomyocytes workflow

Pluripotent stem cell research

Pioneering solutions and integrated workflows for induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs).

hPSCs, either human induced pluripotent stem cells (iPSC) or embryonic stem cells (ES cells), are initially expanded in StemMACS™ iPSC-Brew XF, human or StemMACS PSC-Brew XF, human, allowing the cells to maintain a highly pluripotent phenotype making them well suited for differentiation into any cell type, such as cardiomyocytes. 

Fast and easy iPSC cardiomyocyte differentiation protocol of hPSCs.

StemMACS CardioDiff Kit XF, human has been designed to ease iPSC differentiation to cardiomyocytes in just eight days.

StemMACS CardioDiff Kit XF, human yields high differentiation efficiencies.

This ready-to-use and xeno-free cell culture system ensures high differentiation efficiency with no additional patterning factors, providing you an easy to follow protocol to maintain strong experiment-to-experiment consistency.

Obtain PSC-derived cardiomyoctes as adherent culture or cardiospheres 

StemMACS CardioDiff Kit XF, human can be used with adherent PSC cultures to obtain a monolayer of highly functional PSC-derived cardiomyocytes. Additionally, it can be used to differentiate three-dimensional PSC aggregates into beating cardiospheres. 

Beating cardiomyocytes, derived from an adherent PSC culture that was differentiated with StemMACS CardioDiff Kit XF, human. 

Three-dimensional PSC-derived cardiospheres differentiated with StemMACS CardioDiff Kit XF, human.

Differentiation of ventricular- and atrial-like cardiomyocytes with StemMACS CardioDiff Kit XF, human. 

Obtain ventricular- or atrial-like cardiomyocytes

StemMACS CardioDiff Kit XF, human leads to the generation of ventricular-like cardiomyocytes and, if supplemented with retinoic acid, to atrial-like cardiomyocytes.

StemMACS Cryo-Brew enables cryopreservation of hPSC-derived cardiomyocytes with high recovery and viability after thawing.

hPSC-derived cardiomyocytes can be further maintained with StemMACS Cardiac Cultivation Medium XF, human for up to 30 days. If cells need to be stored for a longer time, they should be cryopreserved in StemMACS Cryo-Brew to maintain their integrity.

hPSC-derived cardiomyocyte characterization.

After thawing, cardiomyocytes should be cultured in StemMACS Cardiac Cultivation Medium XF, human to ensure a fast recovery. In both cases, hPSC-derived cardiomyocytes keep on expressing characteristic markers and show typical morphology.

Cardiomyocyte isolation strategies using the PSC-derived Cardiomyocyte Isolation Kit, human. 

To ensure reliable experimental results, it is critical to work with highly homogeneous cultures of correctly differentiated PSC-derived cardiomyocytes. For this reason, we have developed the PSC-Derived Cardiomyocyte Isolation Kit, human which in contrast to other metabolic selection methods, does not induce any phenotype changes and delivers good yields of highly viable and functional cardiomyocytes. 

Based on magnetic cell separation, PSC-derived non-cardiomyocytes are depleted first before enriching PSC-derived cardiomyocytes in a second step . This not only provides a fast method (45–90 minutes), but also consistently delivers pure cardiomyocyte populations (up to 97% purity) independent of the differentiation protocol, hPSC line used, time point, or efficacy of differentiation. 

Immunophenotyping of cardiomyocytes derived from hPSCs using flow cytometry.

PSC-derived cardiomyocytes comprise a variety of subtypes or subpopulations, such as atrial-like, ventricular-like, and pacemaker-like cells. Characterization has been traditionally done by lengthy and difficult electrophysiological analysis of the respective cell cultures. By contrast, adopting a flow-cytometric characterization approach provides a simpler and time-saving alternative for qualitative and quantitative analysis. 

Our flow cytometry panel for the characterization of PSC-derived cardiomyocyte populations is based on novel recombinantly engineered cardiomyocyte-specific REAfinity™ Antibodies that additionally allow the detection of ventricular and atrial subpopulations.

Get acquainted with our protocols for your workflows in research with pluripotent stem cells.


Seems like you are coming from USA!
Do you want to visit our website in your country?